GILEAD SCIENCES, INC. 4

Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc. (GILD), sold 15,000 shares of common stock on 2026-09-01 for approximately $2.2 million under a Rule 10b5-1 plan.

On September 1, 2026, Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day sold a total of 15,000 shares of Gilead common stock in three open-market transactions executed under a Rule 10b5-1 trading plan adopted on February 25, 2026. The sales were executed at weighted average prices of approximately $147.51 for 1,600 shares, $148.36 for 7,992 shares, and $149.38 for 5,408 shares, implying aggregate proceeds of roughly $2.2 million. Following these planned sales, O'Day's direct ownership decreased to 577,133 shares of Gilead common stock, which, based on the reported sale prices as a proxy for market value, represents an ongoing stake of about $85–$86 million.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

fda

Accession

0001638643-26-000031

Alert Tier

9